2025
We are pleased to have supported Alessandro Tatini, Massimo Ferrati, and HP Sound Equipment SpA in the industrial business combination that led to the acquisition of a majority stake in K-Array Srl—a fast-growing company specializing in the design and production of professional audio systems—by Powersoft SpA, an international group listed on Borsa Italiana and operating globally in the pro-audio sector. This transaction creates a leading market player with an estimated pro-forma aggregated revenue of approximately €88 million and an estimated pro-forma EBITDA approaching €24 million, backed by a team of around 300 professionals among the most experienced in the industry.
2024
Nobel Partners supported the Bassi family in the corporate reorganization process that involved the sale of a majority stake in the GBSAPRI Group to Brera Partners, a Swiss private equity firm specializing in investments in the asset-light financial services sector. The transaction specifically included the sale of 70% of the shares in the Italian insurance broker GBSAPRI to the fund, with the strategy of promoting consolidation in the fragmented Italian insurance brokerage sector.
Headquartered in Rome with 9 offices across Italy, the GBSAPRI Group was founded in 1951 to serve SMEs, businesses, and the public sector. The Group later expanded its portfolio by acquiring local insurance intermediaries in various sectors, covering maritime, cargo, aviation, financial institutions, employee benefits and affinity groups, reinsurance, risk management, and claims management.
2022
Nobel Partners supported Quotidiana in the structuring and execution of the capital raising process on the Mamacrowd equity crowdfunding platform.
The company specifically launched an innovative format of 36 newsstands, 23 of which have already been purchased and 13 launched, transformed into a local multi-service delivery center, a reference point for daily proximity shopping.
The transaction also included an investment of over €700k from the impact fund Sefea Impact SGR.
2022
Nobel Partners Advisory supported 3P Prinz Srl, a manufacturer of pumps for the oil & gas sector, in the transaction involving PCM Group (Gevolet Group), a leading French industrial player in the manufacturing of pumps and systems for the transfer, dosing, lifting, and filling of abrasive, fragile, viscous, corrosive, hot, and heavy products.
The transaction was carried out through a mixed approach of share purchase and capital increase for 40% of 3P Prinz’s capital, to support the strong development of 3P Prinz in research and development, production, and market penetration.
2022
Nobel Partners Advisory assisted Giovanna and Nicoletta Del Carlo in the sale of 80% of the share capital of NT Food S.p.A. to the Morato Group of Vicenza. Morato, an international group in the industrial bakery sector, continues its growth strategy through external expansion with the acquisition of NT Food, which specializes in gluten-free baked goods and is a leader in products for intolerances and alternative dietary regimes. Nicoletta and Giovanna Del Carlo, founding partners of NT Food, will remain at the helm of the company in collaboration with Morato and will continue to hold a minority stake.
2021
Nobel Partners Advisory assisted the Terruzzi family in establishing an industrial partnership with Biofarma Group through a business unit sale transaction. This operation will enable both companies to strengthen their position in the nutraceutical sector and compete at a European level in the healthcare market, while also combining expertise and experience in medical devices and science-based supplements. Giellepi, a company based in the province of Monza and Brianza specializing in the distribution of innovative raw materials for nutraceutical products and the development of dietary supplements and medical devices, will maintain its current corporate structure and management team. It will continue to operate in the raw materials market, enhancing the efficiency and effectiveness of its branded ingredient distribution while continuing to invest in innovation and proprietary clinical studies.